UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other
jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
| (Former name or former address, if changed since last report.) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| The (Nasdaq Capital Market) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement.
On November 19, 2026, CytoSorbents Corporation (the “Company”), a Delaware corporation, entered into two securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (collectively, the “Purchasers”), for the sale by the Company directly to the Purchasers (the “Offering”) of (i) an aggregate of 556,681 shares (the “Common Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $4.94 per share, and 96,527 shares of Common Stock to the Company’s directors and certain executive officers at an offering price of $5.18 per share, which was the consolidated closing bid price of our Common Stock on The Nasdaq Capital Market on November 18, 2026, and (ii) to certain Purchasers, in lieu of Common Stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 151,822 shares of Common Stock (the “Pre-Funded Warrant Shares,” together with the Common Shares, the “Shares”), at a purchase price of $4.939 per Pre-Funded Warrant, equal to the purchase price per Common Share less $0.001, each exercisable for one share of Common Stock at an exercise price of $0.001 per Pre-Funded Warrant Share. The Shares and Pre-Funded Warrants are referred to herein as the “Securities.”
In connection with the Offering, H.C. Wainwright & Co., LLC (“Wainwright”) is acting as exclusive placement agent for the Offering. WBB Securities, LLC (“WBB”) is acting as financial advisor for the Offering, and will receive a financial advisory fee of $30,000 in connection therewith.
The Offering is expected to close on or about November 20, 2026, subject to satisfaction of customary closing conditions set forth in the Purchase Agreements. The gross proceeds from the Offering, before deducting placement agent fees, financial advisor fees and other offering expenses payable by the Company, will be approximately $4.0 million. The Company estimates that net proceeds from the Offering will be approximately $3.5 million. The Company currently intends to use the net proceeds from the Offering for (i) the repayment of $3.0 million of outstanding principal under the Company’s Loan Agreement with Avenue (as defined below), together with a $52,500 prepayment fee and a $270,000 final payment, and (ii) general corporate and working capital purposes.
The Securities were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-281062), which was initially filed with the Securities and Exchange Commission (the “Commission”) on July 26, 2024 and was declared effective by the Commission on September 30, 2024 (the “Registration Statement”), including the base prospectus dated September 30, 2024, as supplemented by a prospectus supplement filed with the Commission on November 20, 2026, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”). In addition, the Registered Shares (as defined below) to be issued to Avenue pursuant to the Avenue Amendment, as described below, are being offered pursuant to the Registration Statement, the base prospectus included therein and the prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act.
The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to the Beneficial Ownership Limitation described below. A holder of a Pre-Funded Warrant may not exercise any such Pre-Funded Warrant to the extent that such exercise would result in the number of shares of Common Stock beneficially owned by such holder and its affiliates exceeding 4.99% or 9.99% (at the election of the holder) of the total number of shares of Common Stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to exceed 9.99% (the “Beneficial Ownership Limitation”).
The Purchase Agreements contain customary representations, warranties, covenants and agreements by the Company and the Purchasers, customary conditions to closing, indemnification obligations of the Company and other obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreements were made only for purposes of the Purchase Agreements and as of specific dates, were solely for the benefit of the parties thereto, and may be subject to qualifications and limitations agreed upon by the contracting parties, including standards of materiality and knowledge that may differ from those applicable to investors generally. Accordingly, such representations, warranties and covenants should not be relied upon as characterizations of the actual state of facts or condition of the Company.
Placement Agent Common Stock Warrant
On October 5, 2026, the Company entered into an engagement letter with Wainwright in connection with the Offering (as amended, the “Engagement Letter”), pursuant to which Wainwright agreed to serve as the exclusive placement agent in connection with the Offering. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 6.0% of the aggregate gross proceeds received by the Company from the Offering, reduced to 3.0% with respect to gross proceeds received from certain existing stockholders of the Company identified in the Engagement Letter, together with their respective affiliates and affiliated funds and accounts (the “Company Investors”), and to issue to Wainwright or its designees warrants (the “Placement Agent Warrants”) to purchase a number of shares of Common Stock (the “Placement Agent Warrant Shares”) equal to 6.0% of the aggregate number of shares of Common Stock (or Common Stock equivalents, if applicable) issued in the Offering, reduced to 3.0% with respect to the shares of Common Stock (or pre-funded warrants in lieu thereof) purchased by the Company Investors. The Company also agreed to pay to Wainwright non-accountable expenses of $50,000, up to $100,000 for its fees and expenses of legal counsel and other out-of-pocket expenses and closing costs, including clearing costs not to exceed $15,950, subject to an aggregate cap of $165,950 on such expenses and reimbursements. The Engagement Letter also includes indemnification obligations of the Company and other provisions customary for transactions of this nature.
The Placement Agent Warrants, exercisable into 18,078 shares of Common Stock, will have an exercise price of $6.175 per share, subject to customary adjustment as provided therein, will be immediately exercisable and will expire on November 19, 2031. Under the terms of the Placement Agent Warrants, the Company may not effect the exercise of any portion of any Placement Agent Warrants, and a holder will not have the right to exercise any portion of any Placement Agent Warrants, which, upon giving effect to such exercise, would cause a holder (together with its affiliates) to own more than a specified beneficial ownership limitation of 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the Placement Agent Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice is delivered to the Company.
The Placement Agent Warrants and the shares of Common Stock issuable upon exercise of the Placement Agent Warrants are not being registered under the Securities Act, were not offered pursuant to the Registration Statement and were offered pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Rule 506(b) promulgated thereunder.
Third Amendment to the Avenue Capital Loan Agreement
Concurrently with the execution of the Purchase Agreements relating to the Offering, the Company entered into the Third Amendment to Loan Documents (the “Avenue Amendment”), dated November 19, 2026, to its existing Loan and Security Agreement with Avenue Capital Group, as amended (the “Loan Agreement”), pursuant to which the Company agreed to restructure certain of its outstanding indebtedness under the Loan Agreement.
Under the terms of the Avenue Amendment, the Company agreed to (i) repay approximately $3.3 million of outstanding indebtedness under the Loan Agreement in cash, consisting of $3.0 million in outstanding principal, a $52,500 prepayment fee and a $270,000 final payment, and (ii) satisfy an additional $2.25 million of outstanding principal through the issuance of shares of Common Stock to Avenue Venture Opportunities Fund, L.P. (“Avenue”) in lieu of repayment in cash. Such shares will be issued at a price per share equal to the purchase price per share of Common Stock sold in the Offering, or $4.94 per share. Of these shares, 202,429 shares, representing the satisfaction of $1.0 million of outstanding principal (the “Registered Shares”), are being issued pursuant to the Registration Statement, the related prospectus and the applicable prospectus supplement, and the remaining 253,036 shares of Common Stock (the “Unregistered Shares” and, together, with the Registered Shares, the “Avenue Shares”), representing the satisfaction of $1.25 million of outstanding principal, are being offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act, and Rule 506(b) promulgated thereunder.
The cash repayment and issuance of shares of Common Stock pursuant to the Avenue Amendment are expected to occur substantially concurrently with the closing of the Offering, subject to satisfaction of the applicable conditions under the Avenue Amendment. Upon issuance of all shares in satisfaction of the additional $2.25 million of outstanding principal, such principal will be deemed paid and satisfied in full. Upon completion of the $3.0 million cash principal repayment and the issuance of shares in satisfaction of the additional $2.25 million of outstanding principal, the Company expects the outstanding principal amount under the Loan Agreement to be reduced by approximately $5.25 million in the aggregate, to a remaining total of $12.25 million of outstanding principal.
The Avenue Amendment also (i) extends the interest-only period through March 31, 2028, subject to a possible three-month extension upon achievement of FDA Marketing Approval and the absence of a continuing event of default, and establishes a maturity date of July 1, 2028; (ii) revises the lenders’ rights to convert up to $3,000,000 of outstanding principal at 140% of the defined Trading Price, or $6.916 per share, and upon the earlier of FDA Marketing Approval or January 1, 2028, up to an additional $3,125,000 of outstanding principal at 175% of that Trading Price, or $8.645 per share, in each case subject to the conditions and limitations in the Avenue Amendment; (iii) imposes a 4.99% beneficial ownership limitation, subject to adjustment on notice, and a 19.99% exchange cap, absent requisite stockholder approval, on issuances upon exercise of the applicable conversion options and warrants; and (iv) increases the applicable cash-burn threshold to $3,200,000 for testing periods through December 31, 2026, with a $2,000,000 threshold otherwise applicable under the amended covenant.
The Avenue Amendment further provides for a $250,000 back-end fee payable to Avenue on July 1, 2028 (or earlier upon repayment or acceleration of the obligations), subject to waiver if Avenue realizes the specified 300% net-profit threshold on the Avenue Shares. It also provides Avenue registration rights with respect to the shares issued in the transaction exempt from registration under the Securities Act, pursuant to which the Company has agreed to file a resale registration statement within 60 days after the Avenue Amendment effective date and to use commercially reasonable efforts to cause it to become effective within 90 days after that date, subject to the terms of the Avenue Amendment. Certain shares issuable to the Lenders upon exercise of conversion options or warrants are subject to a transfer restriction tied to the prohibition period under the Securities Purchase Agreement, as described in the Avenue Amendment.
The foregoing descriptions of the Pre-Funded Warrants, the Placement Agent Warrants, each of the Purchase Agreements and the Avenue Amendment are not complete and are qualified in their entirety by reference to the full text of the Form of Pre-Funded Warrant, the Form of Placement Agent Warrant, each of the Forms of Purchase Agreement and the Avenue Amendment, which are filed herewith as Exhibits 4.1, 4.2, 10.1, 10.2, and 10.3, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.
A copy of the opinion of Morgan, Lewis & Bockius LLP relating to the legality of the issuance and sale of the Shares, the Pre-Funded Warrants and the Registered Shares in the Registered Direct Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.
This Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the expected use of the proceeds from the Offering. There are a number of important factors that could cause actual results to differ materially from those indicated or implied by forward-looking statements. Accordingly, you are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions, including those referenced from time to time in the Company’s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. The Company does not intend to revise or update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise, except as required by law.
Item 3.02 Unregistered Sales of Equity Securities.
The information under Item 1.01 of this Current Report on Form 8-K related to the Placement Agent Warrants, the Placement Agent Warrant Shares and the Unregistered Shares is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On November 20, 2026, the Company issued a press release relating to the items discussed in Item 1.01 of this Current Report on Form 8-K, a copy of which is furnished as Exhibit 99.1 hereto.
The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| November 20, 2026 | CytoSorbents Corporation | ||
| By: | /s/ Dr. Phillip P. Chan | ||
| Name: | Dr. Phillip P. Chan | ||